pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,216 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1788Endpoints1391Fierce Biotech712BioSpace702BioPharma Dive526raps234onclive165fda recalls
therapy area
allOncology12361Rare Disease3229Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • STAT Health Tech newsletter highlights OpenAI health policy ideas and Dexcom CGM updates
    The latest STAT Health Tech newsletter, edited by Mario Aguilar, offers a roundup of recent technology developments in health care. OpenAI proposes a set of health policy recommendations aimed at…
    STAT · 6mo agoNeutral↗ source
  • Oncology fellows urged to nurture curiosity throughout training
    Megan Dupuis, an early-career oncology faculty member at Vanderbilt University Medical Center, shares a story from a rural clinic visit where a patient’s personal background – a one-room schoolhous…
    onclive · 6mo agoPositive↗ source
← prev
page 158 of 169
next →
113
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1062
Pain778
Endocrinology & Metabolism777
Nephrology762
Eugene Braunwald, the "father of modern cardiology," remembered for pioneering heart-attack prevention and a lab scandal
Eugene Braunwald, widely called the father of modern cardiology, died at 96 on April 22. His career reshaped how doctors treat heart disease and he is celebrated as the most influential cardiologis…
STAT · 6mo agoNeutral↗ source
  • Experts caution limited knowledge of hantavirus after outbreak on African offshore cruise ship
    Health officials are monitoring a hantavirus outbreak on the MV Hondius, a cruise ship that was moored off the western coast of Africa. The situation has drawn attention because passengers were con…
    STAT · 6mo agoNeutral↗ source
  • FDA approves nivolumab plus AVD for untreated advanced-stage Hodgkin lymphoma
    Dr. Alex Herrera, a professor and chief of lymphoma at City of Hope, highlighted the recent FDA clearance of the combination of nivolumab with the chemotherapy regimen AVD for patients with newly d…
    onclive · 6mo agoApprovalPositive↗ source
  • GSK signs $1 billion siRNA partnership with China's SiranBio to target obesity
    GSK is expanding its cardiometabolic portfolio by entering a new collaboration with Chinese biotech SiranBio. The agreement is valued at $1 billion in biobucks and focuses on developing siRNA ther…
    Endpoints · 6mo agoDealPositive↗ source
  • Novo Nordisk shares rise as Wegovy updates improve earnings outlook
    Novo Nordisk reported that recent data on its obesity drug Wegovy were less negative than expected, helping the company’s earnings. The improved outlook lifted Novo Nordisk’s share price, narrowin…
    STAT · 6mo agoEarningsPositive↗ source
  • Neoadjuvant T-DXd then THP cuts residual cancer burden vs standard chemo in high-risk HER2-positive breast cancer
    The DESTINY‑Breast11 trial compared three neoadjuvant approaches for patients with high‑risk HER2‑positive early‑stage breast cancer: T‑DxD followed by paclitaxel, trastuzumab and pertuzumab (THP),…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Trump executive order accelerates psychedelic drug development with priority review vouchers, funding and expanded right-to-try
    President Trump signed an executive order that aims to speed the development and approval of psychedelic medicines. The order directs the FDA to issue priority review vouchers, expands right-to-tr…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Eli Lilly to invest $4.5 billion in new manufacturing facilities across Indiana
    Eli Lilly announced a $4.5 billion allocation for new manufacturing projects in Indiana. The company said the funds will be used to build and upgrade production sites across the state, expanding it…
    Endpoints · 6mo agoPositive↗ source
  • Avalo Therapeutics reports Phase 2 success in inflammatory skin disorder and secures $375M financing
    Avalo Therapeutics announced on May 6, 2026 that its experimental immunology drug met its primary endpoints in a Phase 2 study of an inflammatory skin condition. The trial tested two dose levels,…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • New SGO 2026 data show frontline checkpoint inhibitors give 4-year survival boost and almost no relapses after two years in dMMR cancers
    Data presented at the 2026 Society of Gynecologic Oncology meeting highlight the performance of frontline checkpoint inhibitor regimens in patients with deficient mismatch repair (dMMR) cancers. T…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Four-Year Follow-Up Shows Flat Survival Curves with Frontline Checkpoint Inhibitors in dMMR Endometrial Cancer
    Data presented at the 2026 Society of Gynecologic Oncology meeting examined four-year outcomes for patients with dMMR endometrial cancer treated with frontline checkpoint inhibitors. The results s…
    onclive · 6mo agoPositive readoutPositive↗ source
  • Novo Nordisk reports 1 million Wegovy patients and 2.3 bn DKK sales in Q1 amid pricing pressure
    Novo Nordisk's CEO Mike Doustad said the company saw about one million patients using its obesity drug Wegovy during the first quarter. The pill generated sales of roughly 2.3 billion Danish krone…
    Endpoints · 6mo agoEarningsNeutral↗ source
  • Gene therapy leaders in Rome flag FDA regulatory shifts as key challenge
    Gene therapy manufacturers gathered in Rome to discuss the sector’s outlook in Europe, with the U.S. Food and Drug Administration’s recent actions dominating conversation. Speakers highlighted rec…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • White House drug strategy endorses treatment but tightens funding for fentanyl test strips
    The White House released a new drug‑policy document on May 4 that lists public‑health measures such as wider access to the overdose‑reversal drug naloxone, medication‑assisted treatment, and the di…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Experts favor quadruplet regimens for newly diagnosed multiple myeloma, but transplant role remains debated
    At a recent multiple myeloma meeting, Dr. Ajai Chari of UCSF reviewed current frontline treatment strategies for newly diagnosed patients. He said that data from several phase-3 trials have shifte…
    onclive · 6mo agoNeutral↗ source
  • Lonza plans new ADC manufacturing site and workforce boost to capture commercial market
    Lonza said it aims to become a leading supplier of antibody-drug conjugates (ADCs) for commercial use. The Swiss contract manufacturing organization highlighted the growing demand for ADCs and its…
    Endpoints · 6mo agoPositive↗ source
  • FDA accepts supplemental NDA for taletrectinib targeting ROS1‑positive lung cancer
    The U.S. Food and Drug Administration has accepted a supplemental New Drug Application for taletrectinib, a targeted therapy aimed at patients with ROS1‑positive non‑small cell lung cancer. The fi…
    onclive · 6mo agoRegulatoryNeutral↗ source
  • Administration releases detailed report on most-favored-nation drug pricing, projects $529 billion savings
    The White House Council of Economic Advisers released its most detailed analysis yet of the administration's most-favored-nation drug pricing policy. The report defines the MFN pricing approach, w…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Experts highlight lack of reliable biomarkers for melanoma immunotherapy response
    Dr. Mario Sznol, a professor of clinical medical oncology at the University of Miami, discussed the ongoing difficulty of predicting which patients with metastatic melanoma will benefit from immune…
    onclive · 6mo agoNegative↗ source
  • Utah invests in AI supercomputer to boost health research and biotech innovation
    State of Utah announced a major investment in artificial intelligence and high-performance computing infrastructure aimed at accelerating health research. The new AI supercomputer, managed by the…
    onclive · 6mo agoPositive↗ source
  • Expert Consensus Offers Guidance on Evolving Multiple Myeloma Treatment Strategies
    A 2025 expert consensus presented at the Bridging the Gaps meeting highlighted how quickly multiple myeloma care is changing and gave clinicians practical advice for navigating expanding treatment…
    onclive · 6mo agoNeutral↗ source
  • Experts outline PET-CT, biopsy and mutation testing to guide therapy in relapsed CLL
    In a recent discussion, clinicians described the workup for patients with progressive chronic lymphocytic leukemia (CLL). They emphasized using PET‑CT imaging and excisional lymph node biopsy when…
    onclive · 6mo agoNeutral↗ source
  • Experts discuss mutation testing and patient factors to guide second-line CLL therapy after BTK inhibitor resistance
    A 66-year-old man who was diagnosed with chronic lymphocytic leukemia five years ago and initially had an unmutated IGHV profile without TP53 alteration has been on continuous covalent BTK inhibito…
    onclive · 6mo agoNeutral↗ source